文献速递前列腺癌

前列腺癌主动监测中mpMRI表现的自然史:来自队列的启示

The natural history of prostate cancer on MRI: lessons from an active surveillance cohort.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-07-23

该回顾性研究纳入86例接受主动监测(AS)的前列腺癌患者,分析多次mpMRI中可见病灶体积与分级的变化。结果显示43例初始无可见病灶者中5例在中位3.6年随访出现评分≥3/5的病灶;可见病灶体积中位增长10%(p<0.01),但两次扫描间体积测量变异大,可能影响可靠检测。

要点

  • 初始mpMRI无可见病灶者中约17%在中位3.6年随访出现可见病灶。
  • 可见病灶体积中位增长10%,Gleason 3+3者6%、3+4者18%(p=0.058)。
  • 两次扫描间隔<2年时,可见病灶体积测量变异大,可靠检测增长受限。

核心结论

  • 初始无可见病灶的AS患者中17%在中位3.6年随访出现可见病灶。
  • 可见病灶可显示显著增长,但扫描间体积测量变异大,难以可靠检测该幅度增长。

研究设计与样本

  • 回顾性研究纳入86例符合NICE指南接受AS且至少有两次mpMRI(首次在2013年前)的前列腺癌患者。
  • 两名放射科医生在不知患者人口学与扫描日期情况下共识阅片,随机报告以减少偏倚。
  • 对可见病灶在最清晰显示指数肿瘤的序列上用平面测量法测体积并赋予5分Likert评分。

主要发现

  • 43/86例初始mpMRI无可见病灶(≤2/5),其中5/43例在中位3.6年随访出现评分≥3/5的病灶。
  • 40/86例在两次或以上扫描中有评分≥3/5的病灶。
  • 可见病灶体积在3.6年内中位增长10%(p<0.01),Gleason 3+3中位增长6%、3+4中位增长18%(p=0.058)。
  • 35例两次扫描间隔<2年者中,21/35例肿瘤体积中位增加78%,11/35例病灶体积中位减少25%。

关键数值与推荐

  • 初始mpMRI无可见病灶定义为Likert评分≤2/5。
  • 可见病灶定义为Likert评分≥3/5。

临床怎么用

  • AS随访中mpMRI可见病灶体积变化需谨慎解读,扫描间变异可能影响增长判断。
  • 该变异信息可为AS中mpMRI方案及随访扫描间隔的设计提供参考。

局限性

  • 回顾性研究设计。
  • 样本量86例。
  • 两名放射科医生共识阅片,未报告阅片者间一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) is being used increasingly in the setting of active surveillance (AS) for prostate cancer. We investigated changes in the mpMRI appearance of lesions on AS, to show the variability of volume measurements in visible lesions and assess change in lesion size according to grade. METHODS: We retrospectively retrieved 86 men on AS (NICE guidelines) with more than one mpMRI (the first before 2013). Two radiologists, in consensus, were blinded to patient demographics and date of scan. The scans were randomly reported to reduce any bias. For visible lesions, we measured volume by planimetry on the sequence best showing the most conspicuous (index) tumour and attributed a 5-point Likert score. RESULTS: 43/86 men did not have a visible lesion on the initial mpMRI (≤2/5). Of these, 5/43 had developed a lesion scoring ≥3/5 at a median of 3.6 years of follow up. 40/86 had a lesion scoring ≥3/5 on two or more scans. There was a significant increase in volume over 3.6 years by a median of 10% (p < 0.01)-by a median of 6% for Gleason 3+3 and 18% for 3+4 (p = 0.058). Thirty-five men had a visible lesion on two scans separated by <2 years; of these, 21/35 showed a 78% median increase in tumour size between the two scans and 11/35 showed an apparent 25% median decrease in lesion size. CONCLUSIONS: A total of 17% of men with no visible lesion developed a visible lesion at a median follow up of 3.6 years. It is possible to show significant growth in patients with a visible lesion, but variability in volume measurements between scans means that it is difficult to reliably detect increases of this order. This variability may inform the design of mpMRI protocols in AS and the time between follow up scans.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Giganti F, Moore CM, Punwani S, et al. The natural history of prostate cancer on MRI: lessons from an active surveillance cohort. Prostate Cancer Prostatic Dis. 2018. PMID: 30038388. doi:10.1038/s41391-018-0058-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。